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A B S T R A C T
Overdose is the leading cause of unintentional injury-related death. Rhode Island (RI) has the highest rate of
illicit drug use nationally and the 5th highest overdose mortality rate. RI has experienced an outbreak of fen-
tanyl-related overdoses. In incarcerated populations, risk of overdose is greatly elevated. However, little is
known about fentanyl-related overdose post-release. In the current analyses, we identify changes in fentanyl-
related fatal overdose among those who died in 2014 and 2015 who were incarcerated in the year before death.
We linked data from the RI Office of the Medical Examiner with records from the RI Department of Corrections.
We calculated risk ratios and 95% confidence intervals using log-binomial regression to compare risk of fentanyl-
involved overdose death. We also compared median time to death since release, median sentence length, and
median number of incarcerations in 2014 and 2015. Results indicate that the risk of dying of a fentanyl-related
overdose increased (RR: 1.99 (95% CI: 1.11–3.57, p=0.014)) from 2014 to 2015 among those with past year
incarceration. This study is one of the first to describe fentanyl-related fatal overdose among those with past year
incarceration. In 2015 the median sentence was longer among those with a fentanyl-related overdose death and
the median time from release to death among all who had past year incarceration extended past 90 days. Access
to medications for addiction treatment, overdose education, and naloxone should be available during commu-
nity re-entry and extended beyond the early post-release period.
1. Introduction
Overdose is the leading cause of unintentional, injury-related death
in the United States (Warner et al., 2009). Rhode Island (RI) has the
highest rate of illicit drug use nationally and the 5th highest overdose
mortality rate (Rudd, 2016; Substance Abuse and Mental Health
Services Administration, 2014). Like other states, RI is experiencing a
dramatic rise in overdose deaths with an increase of more than 90%
from 2011 to 2016 (Rhode Island Department of Health, 2016). Across
the US, increasing overdose deaths have been accompanied by an
outbreak of fentanyl-contaminated heroin and other drugs. Fentanyl is
a synthetic opioid that is 50–100 times stronger than most other opioids
(O’Donnell et al., 2017; Drug Enforcement Administration, 2017). From
2013 to 2015, overdose deaths that involved synthetic opioids and
heroin increased more sharply than deaths that only included heroin in
the Southern, Midwestern, and Northeastern US (O’Donnell et al.,
2017). The number of fentanyl-involved overdose deaths in RI in-
creased 15-fold from 2009 to 2016 (Rhode Island Department of
Health, 2016). In 2014, 35% of all overdose deaths involved fentanyl,
increasing to 50% in 2016 (Marshall et al., 2017).
In criminal justice (CJ)-involved populations, the risk of overdose is
greatly elevated (Binswanger et al., 2016; Merrall et al., 2010). Nearly a
third of all individuals who are addicted to heroin pass through the CJ
system in any given year, and a majority of those incarcerated in local
jails report issues with substance use (James and Glaze, 2006). Over
23% of state prisoners report ever using heroin or other opiates, and
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We linked data from the RI Office of the Medical Examiner on
overdose deaths (occurring January 1, 2014, to December 31, 2015)
with records from the RIDOC. Data were linked deterministically by
name and date of birth. We calculated risk ratios (RR) and 95% con-
fidence intervals (CI) using log-binomial regression to compare risk of
fentanyl-involved overdose death among those who died in 2014 and
2015 and were incarcerated in the year prior to their death. During the
study period, there were a total of 530 fatal overdoses, and 79 were
among those who had past year incarceration. We also compared
median time to death since release, median sentence length, and
median number of incarcerations in 2014 and 2015.
3. Results
Among those with past year incarceration (n= 79), 35 overdose
deaths (44%) involved fentanyl (see Table 1). The majority of decedents
with past year incarceration were white, male, and aged 18–39. From
2014 to 2015, the total number of overdose deaths in RI increased;
there were 240 overdose deaths in 2014 and 290 in 2015. The number
of overdose deaths among those with past year incarceration remained
relatively steady over the study period, with 35 (14.6%) overdose
deaths in 2014 and 44 (15.2%) in 2015 .
Among all overdose decedents, the number of fentanyl-involved
overdose deaths increased each year as well, with 84 (35%) fentanyl-
involved overdose deaths in 2014 and 136 (47%) in 2015. Among those
with past year incarceration, the proportion of fentanyl-involved
overdose deaths increased significantly from 2014 to 2015 (from 29%
to 56%, p=0.02). The RR for fentanyl-related overdose death among
those with past year incarceration in 2015 compared to 2014 was 1.99
(95% CI: 1.11–3.57, p=0.014).
Among those with past year incarceration, for those whose overdose
death did not involve fentanyl, the median length of sentence decreased
from 50 days in 2014–15 days in 2015 (p=0.1572). However, among
those whose overdose death involved fentanyl, the median length of
sentence increased from 21 days in 2014–58 days in 2015 (p=0.4342).
The median number of past year incarcerations at the RIDOC and the
number of decedents with 30 or fewer days between release and death
remained steady during the study period for all those with past year
incarceration. However, the median days from release to death for both
non-fentanyl-related (99 days to 103 days; p=0.8344) and only fen-
tanyl-related (40 days to 135 days, p=0.2735) deaths among those
with past year incarceration increased from 2014 to 2015. While these
changes were not significant, it is worth noting that, for 2015, in all
overdose deaths among those with past year incarceration the median
time from release to death was over 90 days.
4. Discussion
This is one of only a few recent studies that have described past year
incarceration among people who died of overdose and is the first report
of fentanyl-involved overdose among those with recent incarceration
during the current fentanyl crisis (Marshall et al., 2017; Merrall et al.,
2010). Findings suggest that, compared to 2014, 2015 is marked by a
higher risk of fentanyl-involved deaths for those with past year in-
carceration. Identifying the mechanisms driving the increase in fen-
tanyl-related deaths among those with recent incarceration requires
further investigation, but uncovering the ways that incarceration im-
pacts people during community re-entry is warranted. For instance,
incarceration may lower knowledge of the drug supply’s quality and
possible contamination. During incarceration, people are removed from
their communities and often abstain from drug use. Therefore, when
people are released from jail or prison, they may be unfamiliar with the
presence of fentanyl contaminates in other opioids. In addition, in-
carceration may interrupt people’s regular supply chain. People who
use opioids have reported that maintaining long-term relationships
with dealers, whom they trust to test their products prior to sale, is one
strategy to guard against unwanted fentanyl adulteration (Carroll et al.,
2017). These relationships are disrupted when dealers or users are ar-
rested. Finally, law enforcement-driven responses to the fentanyl
overdose epidemic might also increase the likelihood of incarceration
Table 1
Sociodemographic characteristics of individuals who had a fatal overdose, 2014–2015.
Recent incarceration (n=79) No incarceration (n=451) Recent vs. no
incarceration
Total (n=79) 2015 (n=44) 2014 (n=35) 2015 v.
2014
Total (n=451) 2015 (n=246) 2014 (n=205) 2015 v.
2014
n % n % n % p-value n % n % n % p-value p-value
Race
White 71 89.9 42 95.5 29 82.9 407 90.2 224 91.1 183 89.3
Non-white 8 10.1 2 4.6 6 17.1 0.165 44 9.8 22 8.9 22 10.7 0.542 0.918
Age
18–29 28 35.4 15 34.1 13 37.1 0.780 85 18.8 55 22.4 30 14.6 0.023* 0.000*
30–39 23 29.1 12 27.3 11 31.4 0.693 104 23.1 52 21.1 52 25.4 0.306 0.241
40–49 18 22.8 11 25.0 7 20.0 0.583 104 23.1 48 19.5 56 27.3 0.067 0.957
50+ 10 12.7 6 13.6 4 11.4 0.760 158 35.0 91 37.0 67 32.7 0.333 0.000*
Gender
Male 64 81.0 34 77.3 30 85.7 312 69.2 174 70.7 138 67.3
Female 15 19.0 10 22.7 5 14.3 0.296 139 30.8 72 29.3 67 32.7 0.442 0.039*
Fentanyl 35 44.3 25 56.8 10 28.6 0.013* 185 41.0 111 45.1 74 36.1 0.049* 0.584
Note: for chi-square tests, referent level for race is “white”, reference value for gender is “male”.
* p < 0.05.
13% report regular use before incarceration (Mumola and Karberg, 
2006). Among those incarcerated at the Rhode Island Department of 
Corrections (RIDOC), 18.5% meet the criteria for opioid use disorder; in 
fiscal year 2015, about 12% of all people at the RIDOC were in-
carcerated due to a drug charge (Rhode Island Department of 
Corrections, 2015).
The time immediately after release from jail or prison is a period of 
extreme risk of fatal overdose. In Washington State, overdose death was 
the leading cause of death among those who were recently incarcerated 
(Binswanger et al., 2016). However, very little is known about fentanyl-
related overdose deaths post-release. In the current analyses, we iden-
tify changes in fentanyl-related fatal overdose among those with recent 
incarceration from 2014 to 2015.
5. Conclusion
This study is one of the first to describe fentanyl-related fatal
overdose among those with past year incarceration. Results indicate
that, while the proportion of past year incarceration among those who
died of an overdose in 2014 and 2015 remained steady, the risk of
dying of a fentanyl-related overdose increased. These findings under-
score the importance of comprehensive access to medications for ad-
diction treatment and naloxone during the extended community re-
entry period.
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for drug users and may also explain the increase in median sentence 
length for those with a fentanyl-related overdose in 2015.
The increase in fentanyl-related deaths among those with past year 
incarceration from 2014 to 2015 also demonstrates the need for evidence-
based overdose education and interventions, especially the provision of 
naloxone at release and treatment with medications for addiction treat-
ment. The results of this study provide a strong rationale to prioritize 
training and the provision of the antidote naloxone to individuals leaving 
correctional custody in both jails and prisons, regardless of sentence 
length. Exemplar programs that could be adapted in jail or prison settings 
include the DOPE Project in California and the Harm Reduction Coalition’s 
work in the New York state prison system, both of which have developed 




Most previous research has demonstrated that the early post-release 
period (anywhere from the first two weeks to the first 90 days) is the 
time when recently incarcerated individuals are at the highest risk of 
overdose (Binswanger et al., 2007; Spaulding et al., 2011; Zlodre and 
Fazel, 2012). However, our findings indicate that people may be ex-
periencing fatal overdoses for a more extended period during commu-
nity re-entry, underscoring the importance of continued access to 
medications for addiction treatment and naloxone many months after 
release. The longer median time from release to death may be explained 
by an increase in the number of overdose-related interventions that 
have been rapidly implemented in RI, translating into an uptick in 
services available for individuals immediately after release (Montanaro 
et al., 2015).
Finally, it is worth noting that this study was made possible because 
we were able to match RIDOC data with records from the RI Office of 
the Medical Examiner. Other jurisdictions should similarly link ad-
ministrative datasets to obtain a more comprehensive understanding of 
their local overdose epidemic. Several states and cities such as RI, 
Maryland, and New York City have published reports that can help 
guide this process (Marshall et al., 2017; Cherisco-Hsii et al., 2014; 
Heller et al., 2014)
